More About Our Visiting Professors
Since 2000, The Brent Eley Foundation, in collaboration with the Center for Cancer and Blood Disorders at Children's Hospital Colorado, has hosted an annual guest speaker to address our medical community on cutting-edge developments in pediatric cancer research and treatments. The program enriches the clinical and research experience of oncologists and affiliated specialists in Denver through exposure to internationally recognized experts in their field. The Brent Eley Visiting Professor lectures at both the Anschutz Cancer Center and Children's Hospital Colorado. The talented men and women who have shared their knowledge and experience as a Brent Eley Foundation visiting professor are listed below.
2016: Dr. Rodriguez-Galindo, MD
Director, International Outreach Progra. Chair, Department of Global Peditric Medicine - St. Jude Children's Hospital.
2015: Catherine M. Bollard, MBChB, MD
Director, Program for Cell Enhancement and Technologies for Immunotherapy. Director, Immunology Initiative - Sheikh Zayed Institute for Pediatric Surgical Innovation.
2014: Katherine K. Matthay, MD
University of California San Francisco School of Medicine Chief of Pediatric Hematology/Oncology: UCSF Professor of Pediatrics: Leader, Pediatric Malignancies Program, Helen Diller Family Comprehensive Cancer Center: Mildred V. Strouss Professor of Translational Research in Childhood Cancer.
Dr. Matthay is one of the world's leading doctors and researchers in treatments for childhood cancer. She directs at 16-institution consortium (New approaches to Neuroblastoma Therapy - www.nant.org) to test new therapies for neuroblastoma. She is also actively collaborating in laboratory studies of the genetics of and new therapies for neuroblastoma, and has helped to direct several phase 3 clinical trials in the Children's Oncology Group. Since 1988, Dr. Matthay has held several leadership positions in national pediatric cooperative clinical research groups, including serving as a chair for 10 years of the Children's Cancer Group Neuroblastoma Disease Committee.
Dr. Matthay earned an undergraduate degree in chemistry at Bryn Mawr College in Pennsylvania and a medical degree at the University of Pennsylvania in Philadelphia. She completed a residency in pediatrics at the University of Colorado in Denver and a fellowship in pediatric hematology and oncology at UCSF Medical Center. She has been the chief of Pediatric Hemotology-Oncology at UCSF since 2003.
2013: William L Carroll, MD
Julie and Edward J. Minskoff Professor of Pediatrics, Director of NYU Cancer Institute and the Pediatric Hematology Oncology Program at NYU Medical Center.
Dr. Carroll is the Head of the Children's Oncology Group Acute Lymphoblastic Leukemia Disease Committee and is responsible for developing and directing clinical research in North America for children with acute lymphoblastic leukemia (ALL), the most common childhood cancer. He has played an active role throughout his career in ALL research and the development of national ALL clinical trials.
Dr. Carroll has extensive experience in all aspects of the care of children with cancer and blood diseases. His medical expertise is in bone marrow transplantation. lymphoma, pediatric hematology/oncology, bone marow failure, stem cell transplant, transplant infections, childhood cancers non-hodgkin's lymphona and leukemia.
2012: Paul Sondel, MD, PhD
Head of Department of Pediatric Hematology and Oncology and Professor of Pediatrics, Human Oncology and Medical Genetics, UW-Madison School of Medicine and Public Health
Dr. Sondel joined the UW-Madison faculty in 1980 and became Head of the Department of Pediatric Hematology and Oncology in 1990. He also leads the UW Carbone Cancer Center's Program/Working Group in Cancer Immunology and Immunotherapy, is the Chair of the ICTR Scientific Review Committee and is Associate Director for Translational Research.
Dr. Sondel earned his bachelor's degree and PhD in Genetics from UW-Madison, with guidance from Bone Marrow Transplant pioneer, Fritz Bach, M.D. He earned his medical degree magna cum laude from Harvard Medical School. His research focuses on the hypothesis that the immune system can have a beneficial impact on treating cancer. His most recent studies involve the preclinical and clinical development of a humanized antibody that recognizes a tumor antigen that is linked to human recombinant IL-2, a fusion protein now in clinical trials at the UW Carbone Cancer Center.
2011: Dr. Kathleen Sakamoto
Chief of Pediatric Hematology/Oncology and Professor of Pathology and Laboratory Medicine, UCLA
Dr. Kathleen Sakamoto joined the Division of Hematology/Oncology, Department of Pediatrics at the David Geffen School of Medicine at UCLA in 1993 and has continued to study the signaling pathways that control leukemia cell growth.
Dr. Sakamoto pursued her Ph.D. degree at California Institute of Technology, where she developed a new approach to cancer therapy that targets the cell's own destruction machinery. She is currently Professor and Chief of Pediatric Hematology/Oncology, Vice-Chair of Research at the Mattel Children's Hospital UCLA, and Program Director of the UCLA Fellowship Program.
2010: Dr. Mignon Loh
Associate Professor of Clinical Pediatrics, University of California, San Francisco
Dr. Mignon Loh is a pediatric cancer specialist with a particular interest in the treatment of children with leukemia, lymphoma and sarcomas. She earned a bachelor's degree at Bryn Mawr College in Pennsylvania and her MD at Columbia University. She served as an instructor at Harvard Medical School and as a research fellow at Brigham and Women's Hospital in Boston.
Dr. Loh’s research interests are split between two diseases, juvenile myelomonocytic leukemia (JMML) and acute lymphoblastic leukemia (ALL). Her research broadly involves the identification, significance, and functions of genetic mutations in pediatric leukemia and consists of clinical-translational studies in pediatric leukemia.
2009: Michael Link, MD
Service Chief, Division of Pediatric Hematology/Oncology and Lydia J. Lee Professor in Pediatric Oncology, Lucile Packard Children’s Hospital at Stanford.
Dr. Michael Link received his MD at Stanford University School of Medicine. He served his internship and residency at Children’s Hospital of Boston as well as a Fellowship at Children’s Hospital of Boston and Dana-Farber Cancer Institute in Boston, MA. He has enjoyed 31 years on staff at the Lucile Packard Children’s Hospital at Stanford.
2008: Peter C. Adamson, MD
Chief, Division of Clinical Pharmacology & Therapeutics, Director, Experimental Therapeutics in Oncology, Professor of Pediatrics, University of Pennsylvania School of Medicine.
Dr. Peter C. Adamson earned his MD at Cornell University Medical College in New York, followed by residency at The Children’s Hospital of Philadelphia and a Fellowship at the National Cancer Institute in Washington, D.C. He is board certified by the American Board of Pediatrics/Pediatric Hematology-Oncology and Clinical Pharmacology. His special interest is new investigational drugs for childhood cancer and he was recently selected as Chair of the Children’s Oncology Group (COG), a group of more than 200 centers that brings together 5,000 international experts in childhood cancers.
2007: Richard J. Gilbertson, MD
Co- Leader, Neurobiology and Brain Tumor Program, Director, Molecular Clinical Trials Core, Department of Developmental Neurobiology and Oncology, St. Jude Children’s Research Hospital.
Dr. Richard J. Gilbertson’s research aims to reduce the morbidity and mortality of children with central nervous system tumors through improved understanding of tumor biology.
2006: John M. Maris, MD
Chief, Division of Oncology, Giulio D’Angio Chair of Neuroblastoma Research, Director for Center for Childhood Cancer Research and Associate Professor of Pediatrics, University of Pennsylvania School of Medicine.
Dr. John M. Maris received his undergraduate degree from Wheeling College in West Virginia and his MD from the University of Pennsylvania School of Medicine. He served his residency and a Hematology/Oncology Fellowship at The Children’s Hospital of Pennsylvania in Philadelphia, PA. His research is focused on molecular genetics and treatment of neuroblastoma, a common and often devastating childhood cancer of the peripheral nervous system.
2005: Stella M. Davies, MBBS, PhD, MRCP
Director of Division of Bone Marrow Transplantation and Immune Deficiency, Jacob G. Schmidlapp Endowed Chair and Professor of Pediatrics, Cincinnati Children’s Hospital.
Dr. Stella M. Davies received her MBBS with First Class Honors from the University of Newcastle-Upon-Tyne, England with clinical and Fellowship training at The Royal Victoria Infirmary, Newcastle General Hospital and Great Ormond St. Hospital. She received her Ph.D. in Molecular Biology form University of Newcastle-Upon-Tyne and served her Pediatric Fellowship in Hematology/Oncology and Bone Marrow Transplantation at the University of Minnesota, Minneapolis, MN. She has received numerous awards, including Best Doctors in America 2008, “2005 Best Doctors” and “2004 Best Doctors”. Her research includes Host Factors and Etiology of Leukemia, Molecular Genetics in Childhood Cancer Survivors and Epidemiology of Infant Leukemia.
2004: Alan D'Andrea, MD
The Alvan T. and Viola D. Fuller American Cancer Society Professor of Radiation Oncology, Harvard Medical School
Dr. Alan D’Andrea received his MD from Harvard Medical School and served his residency in Pediatrics at Children’s Hospital of Philadelphia and fellowship training in pediatric hematology-oncology at Dana-Farber Cancer Institute (DFCI) and Children's Hospital Boston (CHB). He completed a research fellowship at the Whitehead Institute and joined DFCI in 1990. He is also scientific director of the DFCI Molecular Diagnostics Laboratory and director of the Clinical Gene Therapy Center at CHB.
His research focus is on Chromosome Instability and Susceptibility to Cancer.
2002: Richard O'Reilly, MD
Chairman, Department of Pediatrics; Chief, Bone Marrow Transplant Service, Claire L. Tow Chair in Pediatric Oncology Research, Memorial Sloan-Kettering Cancer Center, New York City.
Dr. Richard O’Reilly earned his MD from University of Rochester School of Medicine, served residencies at University of Minnesota Hospitals and Children’s Hospital Medical Center in Boston, and fellowships at Children’s Hospital Medical Center and Beth Israel Hospital, both in Boston. His clinical expertise is Pediatric Oncology; Allogenic and Autologous Bone Marrow and Peripheral Blood Stem Cell Transplantation; and Congenital and Acquired Diseases of Hematopoiesis and Immunity.
2001: Todd Golub, MD
Charles A. Dana Investigator in Human Cancer Genetics, Dana-Farber Cancer Institute (DFCI), Associate Professor of Pediatrics at Harvard Medical School, Boston MA; Director of Cancer Genomics, Whitehead Institute/MIT Center for Genome Research
Dr. Todd Golub received his MD from the University of Chicago. After completing his subspecialty clinical and research training at Harvard Medical School, he joined DFCI. His research focus is on Genomic Approaches to Cancer.
2000: Malcolm Brenner, MD, PhD
Professor, Department of Pediatrics, Section of Hematology-Oncology and Director, Shell Center for Gene Therapy, Baylor College of Medicine. Director, Center for Cell and Gene Therapy, Texas Children’s Hospital.
Dr. Malcolm Brenner earned his M.B.Ch.B. and Ph.D. from Cambridge University, London, England and served Fellowships at the Royal College of Pathologists and Royal College of Physicians. His clinical special interests are Cell and Gene Therapy, Oncology, and Bone Marrow Transplantation.